Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802994 · ClinicalTrials.gov registry record · Early Phase 1
Pneumococcal Conjugate Vaccine in Aging Renal Transplant
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 57
- Enrollment target
NCT03802994: Clinical Trial Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT03802994 is a Early Phase 1 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 57 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03802994, a Early Phase 1 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. The investigators will study differences in the kind of B cells and markers on the B cells that are known to be important in the response to the pneumonia vaccine in aging renal transplant and aging dialysis recipients compared to similarly aged and young healthy controls. Finally, the investigators will study how safe the pneumonia vaccine is in aging renal transplants. The answers to these questions will help in designing a better vaccine for older people with a renal transplant or on dialysis.
Primary Outcome
Measure the opsonic antibody response against streptococcus pneumonia serotypes 14, 19A and 23F at days 0 and 30. Comparing elderly RT recipients versus healthy elderly and elderly with DM/HTN.
Interventions
- OTHER Peripheral blood sample
- BIOLOGICAL 13 valent conjugated pneumococcal vaccine
- DRUG 23 valent pneumococcal polysaccharide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2020-02-28 |
| Phase | Early Phase 1 |
Why NCT03802994 stopped before completion
NCT03802994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Peripheral blood sample is the first listed.
NCT03802994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03802994 about?
NCT03802994 is a clinical study titled "Pneumococcal Conjugate Vaccine in Aging Renal Transplant". The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. ...
What is the current status of trial NCT03802994?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 57 participants. The study started on 2018-11-01. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT03802994?
The interventions under investigation include: Peripheral blood sample (OTHER), 13 valent conjugated pneumococcal vaccine (BIOLOGICAL), 23 valent pneumococcal polysaccharide vaccine (DRUG).
Who is sponsoring clinical trial NCT03802994?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03802994's enrollment target sits among peer trials
57 446th of 2000 higher than 1,550 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI